Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

Summary

Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. There is no standard second-line treatment plan for patients who have failed first-line treatment. NY-ESO-1, a cancer testis antigen, is highly expressed in soft tissue tumors and is an ideal therapeutic target. Investigators aim to testify the safety and efficacy of NY-ESO-1 TCR-T cell in advanced soft tissue sarcoma.

Timeline

Start

2022-11-11

Primary completion

2025-12-01

Completion

2028-12-01

Drugs

Indications